IO Biotech ( ($IOBT) ) has issued an update. IO Biotech, Inc. faced a compliance issue with Nasdaq’s minimum bid price requirement when its stock ...

HONG KONG: China and Hong Kong stocks extended gains on Wednesday, supported by a rally in biotech and rare earth shares and ...

Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive. However, a recent move Eli Lilly made reveals an underrated reason why the stock has attractive prospects.

Is the right time to invest in some top-performing US penny stocks? Here's a look at some of the top-performing ones from ...

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

The ASX biotech sector dipped slightly in value in May, but stocks such as Medadvisor and Dimerix recorded lusty gains.

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...